ARCHIVES

Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials.

This article is from The Cancer Letter archive.

Vol. 30 No. 39 | October 15, 2004

Download PDF Visit The Full Archive

Related Articles

New Biomarker Findings Show Improvement in KRAS Subtype In Phase III Erbitux Trial

May 30, 2014

Gleevec Better Than Interferon For Newly Diagnosed CML

May 31, 2002

Key Cancer Legislation Remains Unfinished as Congress Departs for Election.

October 6, 2006

In Brief: Pretreatment Critical In Antimetic Therapy, Sallan Says; Aging/Cancer Symposium Planned

July 11, 1980

NCI Community Intervention Trial Reports

March 10, 1995

ASCO Updates Guideline On Antiemetics

June 30, 2006